Published in:
01-07-2016 | Erratum
Erratum to: The treatment with pasireotide in Cushing’s disease: effects of long–term treatment on tumor mass in the experience of a single center
Published in: Endocrine | Issue 1/2016
Login to get accessExcerpt
In the original publication, some of the units in Tables 1, 2 and 3 are not correctly reported; in detail, throughout the text and tables, pituitary tumor volume is expressed in ml instead of mm3. The corrected version of Tables 1, 2 and 3 are given below.
Table 1
Patient’s profile at study entry
|
Patients number
|
8
|
|
Patients Age (years)
|
38.9 ± 17.6
|
|
Microadenoma nr. (%)
|
7 (87.5)
|
|
Macroadenoma nr. (%)
|
1 (12.5)
|
|
Tumor volume (mm3)
|
416.46 ± 937.07
|
|
UFC (nmol/24h)
Median pasireotide starting dose (µg bid)
|
771.75 ± 606.57
900
|
Table 2
Patient 1: Patient’s profile before and after 3, 6, 12, 18, 21 and 24 months of pasireotide treatment
|
Parameters
|
Normal range
|
Baseline
|
3 months
|
6 months
|
Δ%a
|
12 months
|
Δ%a
|
18 months
|
21 months
|
24 months
|
Δ%a
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Weight (kg)
|
–
|
104.5
|
95.5
|
89
|
−14.8
|
81.5
|
−22
|
83
|
82.1
|
81
|
−22.5
|
|
BMI (kg/m2)
|
20–25
|
35.3
|
32.2
|
30
|
−15
|
27.5
|
−22.1
|
28
|
27.7
|
27.3
|
−22.7
|
|
Waist circumference (cm)
|
<88
|
119
|
112
|
103
|
−13.4
|
104
|
−12.6
|
98
|
103
|
97
|
−18.5
|
|
Ferriman–Gallwey score
|
<8
|
30
|
32
|
28
|
−6.7
|
23
|
−23.3
|
19
|
18
|
14
|
−53.3
|
|
HR QoL score
|
–
|
41
|
48
|
56
|
+36.6
|
50
|
+21.9
|
–
|
–
|
–
|
|
|
BDI–II score
|
–
|
9
|
3
|
0
|
−100
|
1
|
−88.9
|
0
|
0
|
0
|
−100
|
|
SBP (mmHg)
|
<130
|
120
|
115
|
120
|
0
|
125
|
+4.2
|
130
|
120
|
112
|
−6.7
|
|
DBP (mmHg)
|
<85
|
70
|
70
|
80
|
+14.3
|
70
|
0
|
80
|
80
|
70
|
0
|
|
Fasting glucose (mmol/L)
|
3.9–6.9
|
6.3
|
5.7
|
5.1
|
−19
|
7.2
|
+14.3
|
6.1
|
6.5
|
6.1
|
−3.2
|
|
Insulin (mU/L)
|
3–25
|
81.6
|
21
|
83.3
|
+2.1
|
14.8
|
−81.9
|
24.4
|
14.6
|
40.3
|
−50.6
|
|
HBA1C (%)
|
3.5–6
|
5.5
|
–
|
6
|
+9.1
|
6.9
|
+25.4
|
6.6
|
6.9
|
7
|
+27.3
|
|
Total cholesterol (mmol/L)
|
2.2–5.2
|
5.3
|
4.8
|
4.9
|
−7.5
|
4.8
|
−9.4
|
4.8
|
5.1
|
4.8
|
−9.4
|
|
LDL cholesterol (mmol/L)
|
1.6–3.3
|
3.1
|
2.7
|
2.8
|
−9.7
|
2.9
|
−6.4
|
2.7
|
3
|
2.8
|
−9.7
|
|
HDL cholesterol (mmol/L)
|
>1.3
|
1.4
|
1.42
|
1.6
|
+14.3
|
1.5
|
+7.14
|
1.68
|
1.64
|
1.34
|
−4.3
|
|
Triglycerides (mmol/L)
|
0.3–1.7
|
3.7
|
3.4
|
2.5
|
−32.4
|
2.1
|
−43.2
|
2.1
|
2.3
|
3.3
|
−10.8
|
|
BMD lumbar vertebrae (mg/cm3)
|
–
|
0.962
|
–
|
1.011
|
+5.1
|
1.002
|
+4.1
|
–
|
–
|
0.983
|
+2.2
|
|
BMD proximal femur total hip (mg/cm3)
|
–
|
NP
|
–
|
1.012
|
–
|
NP
|
–
|
–
|
–
|
0.916
|
–
|
|
BMD proximal femur neck (mg/cm3)
|
–
|
NP
|
–
|
0.972
|
–
|
0.838
|
–
|
–
|
–
|
0.856
|
–
|
|
Plasma ACTH (ng/L)
|
0–46
|
101
|
75
|
80
|
−20.8
|
82
|
−18.8
|
86
|
91
|
72
|
−28.7
|
|
Serum cortisol (nmol/L)
|
119–618
|
634
|
440
|
628
|
−0.95
|
574
|
−9.5
|
498
|
682
|
381
|
−39.9
|
|
Mean UFC (nmol/24 h)
|
30–145
|
535
|
132
|
138
|
−74.2
|
162
|
−69.7
|
127
|
145
|
111
|
−79.2
|
|
MRI: pituitary tumor diameters (mm)
|
–
|
15 × 21 × 17
|
–
|
11 × 15 × 12
|
–
|
10 × 12 × 8
|
–
|
–
|
–
|
9 × 12 × 8
|
–
|
|
MRI: pituitary tumor volume (mm3)b
|
–
|
2731.05
|
–
|
1009.8
|
−63
|
489.6
|
−82
|
–
|
–
|
440.6
|
−84
|
Table 3
Patient 2: Patient’s profile before and after 3, 6, 12, 18, 21 and 24 months of pasireotide treatment
|
Parameters
|
Normal range
|
Baseline
|
3 months
|
6 months
|
Δ%a
|
12 months
|
Δ%a
|
18 months
|
21 months
|
24 months
|
Δ%a
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Weight (kg)
|
–
|
61
|
60
|
56.5
|
−7.4
|
52.5
|
−13.9
|
55
|
56.7
|
56
|
−8.2
|
|
BMI (kg/m2)
|
20–25
|
20.4
|
20
|
18.89
|
−7.4
|
17.55
|
−14
|
18.39
|
18.96
|
18.72
|
−8.2
|
|
Waist circumference (cm)
|
<88
|
80
|
80
|
84
|
+5
|
72
|
−10
|
75
|
75
|
73
|
−8.75
|
|
Ferriman–Gallwey score
|
<8
|
11
|
3
|
1
|
−90.9
|
1
|
−91
|
1
|
1
|
1
|
−90.9
|
|
HR QoL score
|
–
|
37
|
31
|
35
|
−5.4
|
41
|
+10.8
|
–
|
–
|
–
|
–
|
|
BDI–II score
|
–
|
21
|
23
|
20
|
−4.8
|
17
|
−19
|
12
|
8
|
6
|
−71.4
|
|
SBP (mmHg)
|
<130
|
110
|
100
|
102
|
−7.3
|
105
|
−4.5
|
110
|
100
|
100
|
−9.1
|
|
DBP (mmHg)
|
<85
|
70
|
70
|
60
|
−14.3
|
65
|
−7.1
|
70
|
70
|
60
|
−14.3
|
|
Fasting glucose (mmol/L)
|
3.9–6.9
|
4.1
|
4.1
|
4.3
|
+4.9
|
4.2
|
+2.4
|
4.7
|
3.9
|
4.3
|
+4.9
|
|
Insulin (mU/L)
|
3–25
|
21.3
|
7.7
|
5.9
|
−72.3
|
5.4
|
−74.6
|
4.8
|
16.1
|
5.4
|
−74.6
|
|
HBA1C (%)
|
3.5–6
|
5.4
|
–
|
5.6
|
+3.7
|
5.3
|
−1.85
|
5.6
|
5.7
|
5.8
|
+7.4
|
|
Total cholesterol (mmol/L)
|
2.2–5.2
|
5.4
|
4.8
|
4.2
|
−22.2
|
4.5
|
−16.7
|
5.1
|
5.6
|
5.4
|
0
|
|
LDL cholesterol (mmol/L)
|
1.6–3.3
|
2.6
|
2.5
|
2.1
|
−19.2
|
2.2
|
−15.4
|
2.6
|
2.7
|
2.9
|
+11.5
|
|
HDL cholesterol (mmol/L)
|
>1.3
|
2.64
|
2.12
|
1.98
|
−25
|
2.18
|
−17.4
|
2.34
|
2.76
|
2.36
|
−10.6
|
|
Triglycerides (mmol/L)
|
0.3−1.7
|
0.8
|
0.9
|
0.6
|
−25
|
0.6
|
−25
|
0.8
|
0.7
|
0.7
|
−12.5
|
|
BMD lumbar vertebrae (mg/cm3)
|
–
|
0.822
|
–
|
0.815
|
−0.6
|
0.8
|
−2.4
|
–
|
–
|
0.769
|
−6.2
|
|
BMD proximal femur total hip (mg/cm3)
|
–
|
0.656
|
–
|
0.647
|
–0.5
|
NP
|
–
|
–
|
–
|
0.669
|
+2.9
|
|
BMD proximal femur neck (mg/cm3)
|
–
|
0.723
|
–
|
0.726
|
+0.4
|
0.473
|
−34.6
|
–
|
–
|
0.748
|
+3.45
|
|
Plasma ACTH (ng/L)
|
0–46
|
32
|
13
|
13
|
−59.4
|
22
|
−31.25
|
22
|
20
|
21
|
−34.4
|
|
Serum cortisol (nmol/L)
|
119–618
|
495
|
287
|
322
|
−34.9
|
512
|
+3.4
|
584
|
492
|
573
|
+15.7
|
|
Mean UFC (nmol/24 h)
|
30–145
|
580
|
20
|
48.5
|
−91.6
|
85.75
|
−85.2
|
88
|
182
|
221.5
|
−61.8
|
|
MRI: pituitary tumor diameters (mm)
|
–
|
6 × 7 × 6
|
–
|
2.5 × 2.8 × 3
|
–
|
0
|
–
|
–
|
–
|
0
|
–
|
|
MRI: pituitary tumor volume (mm3)b
|
–
|
128.5
|
–
|
10.71
|
−91.7
|
0
|
−100
|
–
|
–
|
0
|
−100
|